As summer approaches, millions of Americans are turning to weight-loss injections in hopes of shedding pounds—fast. Roughly ...

Eli Lilly ( LLY 2.92%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide ... tirzepatide achieved at least 25% body weight loss compared to 16.1% of those receiving ...

Medications targeting weight loss like Wegovy and Zepbound are part of a relatively ... as not only life-changing but also lifesaving. The results have led to a surge in popularity in recent ...

Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the ...

Drugmaker Eli Lilly announced promising Phase 3 study results ... diabetes and weight loss. The drug is in the same class of GLP-1 medications as Ozempic, Wegovy, Mounjaro, and Zepbound ...

Currently, only liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound ... your potential results, it can increase the likelihood of maintaining weight loss in the long term.